Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity

Human immunodeficiency virus-infected women with central adiposity switched to raltegravir-based antiretroviral therapy immediately or after 24 weeks. No statistically significant changes in computed tomography-quantified visceral adipose tissue (VAT) or subcutaneous fat were observed, although 48 w...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Open Forum Infect Dis
Egile Nagusiak: Lake, Jordan E., McComsey, Grace A., Hulgan, Todd, Wanke, Christine A., Mangili, Alexandra, Walmsley, Sharon L., Currier, Judith S.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2015
Gaiak:
Brief Reports
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4567084/
https://ncbi.nlm.nih.gov/pubmed/26380350
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofv059
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak